OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts
Daniele Santini, Giuseppe Luigi Banna, Sebastiano Buti, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 11, pp. 1345-1362
Open Access | Times Cited: 7
Daniele Santini, Giuseppe Luigi Banna, Sebastiano Buti, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 11, pp. 1345-1362
Open Access | Times Cited: 7
Showing 7 citing articles:
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
Aruni Ghose, Patricia Lapitan, Vedika Apte, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 6, pp. 633-646
Closed Access | Times Cited: 4
Aruni Ghose, Patricia Lapitan, Vedika Apte, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 6, pp. 633-646
Closed Access | Times Cited: 4
Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology
Giorgio Calleris, Markus von Deimling, Claudia Kesch, et al.
Current Opinion in Urology (2024) Vol. 34, Iss. 3, pp. 217-224
Closed Access | Times Cited: 2
Giorgio Calleris, Markus von Deimling, Claudia Kesch, et al.
Current Opinion in Urology (2024) Vol. 34, Iss. 3, pp. 217-224
Closed Access | Times Cited: 2
Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale
Makito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Journal of Chemotherapy (2024), pp. 1-13
Closed Access | Times Cited: 2
Makito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Journal of Chemotherapy (2024), pp. 1-13
Closed Access | Times Cited: 2
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
Maxim Noeraparast, Katarina Krajina, Renate Pichler, et al.
Cancer Communications (2024) Vol. 44, Iss. 10, pp. 1189-1208
Open Access | Times Cited: 2
Maxim Noeraparast, Katarina Krajina, Renate Pichler, et al.
Cancer Communications (2024) Vol. 44, Iss. 10, pp. 1189-1208
Open Access | Times Cited: 2
Differential expression of WNT5A long and short isoforms in non-muscle-invasive bladder urothelial carcinoma.
Amy M Strope, Cody Phillips, Sabin Khadgi, et al.
PubMed (2024) Vol. 39, Iss. 6, pp. 715-727
Closed Access
Amy M Strope, Cody Phillips, Sabin Khadgi, et al.
PubMed (2024) Vol. 39, Iss. 6, pp. 715-727
Closed Access
Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China
Kehui Meng, Heng Xiang, Mei-Yu Wu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Kehui Meng, Heng Xiang, Mei-Yu Wu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
